A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

In a recent article titled “ Big Pharma says ‘Thanks, but No Thanks’ to their own HEOR groups, ” Professor Scott Ramsey from ...

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

Statistically significant means there is a very high likelihood the drug impacted its target. But if data are not clinically ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies strategies ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI ponders the next big developments and breakthroughs he expects to see in the ...

Monica Martin de Bustamante, senior partner and head of advisory at Trinity Life Sciences, spoke with Pharmaceutical ...